Overview
Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects
Status:
Completed
Completed
Trial end date:
2008-04-01
2008-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will evaluate the safety and tolerability of single and multiple doses of VAK694 in healthy volunteers and otherwise healthy volunteers with a history of allergies.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Novartis
Criteria
Inclusion Criteria:- History of allergic rhinitis (Part 2 only)
Exclusion Criteria:
- Very low or high body weight
- Heavy or recent smoker
- Exposure to human monoclonal antibodies
Other protocol-defined inclusion/exclusion criteria may apply.